NGENLA™ is an FDA-approved next-generation human growth hormone therapy for patients with pediatric growth hormone deficiency. Now approved in over 40 markets worldwide through our partnership with Pfizer, NGENLA™ has the potential to transform the human growth hormone treatment landscape by offering patients a next-generation innovative medicine. Learn more about NGENLA™ and our other marketed therapy, RAYALDEE®.
Learn MoreWe believe the future of medicine will be multispecific. Our research efforts are focused on advancing multispecific therapies that have the potential to treat the multifaceted drivers of serious conditions including cancers and infectious disease. Our R&D team is comprised of the former leaders of N.I.H., Sanofi and other leading scientific organizations and our programs have attracted partnerships with Merck, N.I.H., and BARDA.
Learn MoreAs one of the largest full-service clinical reference laboratories in the U.S., serving approximately 11 million patients annually, BioReference Laboratories is a leading diagnostics company that continues to deliver innovations for patients and physicians, particularly those working in specialty areas.
Learn MoreWe have a proven track record of partnering with the world’s leading organizations who seek out our scientific expertise in developing next-generation therapies. By partnering with global companies on attractive terms, we’re able to ensure the transformative potential of our research reaches the largest number of patients around the world.
